| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Cargo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $507.54M | Series A-1 | 7/31/2023 | $86.04M | $302.29M | $13.57 | Ally Bridge Group, Cormorant, NexTech, Piper Heartland, Piper Sandler, RTW Sandler, RTW Investments, Third Rock Ventures, T. Rowe Price, Wellington, Xontongey, Janus Henderson, Emerson Collective, Red Tree Venture, Samsara BioCapital, Cormorant Capital | ||||
 | Clarus Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.16M | Series D | 6/12/2014 | $81.23M | $174.1M | $4.50 | Thomas McNerney & Partners, C-Bridge Capital, BVCF | ||||
 | Conformal | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $122.03M | Series D | 6/5/2023 | $35M | $288.39M | $5.08 | SPRIG Equity, Fidelity | ||||
 | Contineum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $133.61M | Series C | 2/11/2021 | $80.4M | $244.63M | $2.68 | Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, Versant Ventures, Sectoral Asset Management, Cleva Pharma | ||||
 | Entrada Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $204.63M | Series B | 3/31/2021 | $116.25M | $360.98M | $15.72 | Wellington Management, Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority, Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures, 5AM Ventures, MPM Capital, Roche Venture Fund, MSD, Agent Capital | ||||
 | Goldfinch Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190.22M | Series B | 6/30/2020 | $105.91M | $252.06M | $1.18 | Eventide Asset Management, Wellington Management Company, Ally Bridge Group, BlackRock, Casdin Capital, Irving Investors, Gilead Sciences, Yonjin Capital, Schroeder Adveq | ||||
 | HealthJoy | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $87.95M | Series D | 10/27/2022 | $35M | $179.66M | $2.70 | Valspring Capital, Endeavour Vision, CIBC Innovation Banking, U.S. Venture Partners, Brandon Cruz, Clint Jones, Health Velocity Capital, Nueterra Capital, EPIC Ventures | ||||
 | IDRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $242.24M | Series B | 8/7/2024 | $120.24M | $414.65M | $6.44 | RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest | ||||
 | Immune-Onc Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $143.15M | Series B3 | 1/6/2023 | $30M | $262.2M | $2.11 | Triwise Capital, Proxima Ventures | ||||
 | IsoPlexis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.52M | Series D | 1/7/2021 | $92.5M | $348.21M | $76.92 | Perceptive Advisors, Ally Bridge Group, BlackRock | ||||
 | LocanaBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $318M | Series B | 12/14/2020 | $100M | $317.84M | $4.42 | Vida Ventures, RA Capital Management, Invus, Acuta Capital Partners, ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures, GV | ||||
 | Metabiota | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $84.22M | Series B | 3/7/2017 | $8.02M | $156.11M | $1.84 | WP Global Partners, In-Q-Tel, SharesPost | ||||
 | Neogene Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125M | Series A | 9/14/2020 | $110M | $241.63M | $12.47 | EcoR1 Capital, Jeito Capital, Syncona, Polaris Partners, Pontifax, Vida Ventures, TPG, Two River | ||||
 | Nurx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.87M | Series C-1 | 8/11/2020 | $13.31M | $317.71M | $7.32 | Wittington Ventures, Union Square Ventures, Trustbridge Partners, Kleiner Perkins, Comcast Ventures | ||||
 | PatientPop | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.82M | Series C | 8/25/2020 | $42.65M | $425.93M | $9.93 | HLM Venture Partners, Commonfund, Vivo Capital, Toba Capital, Transformation Capital, Silicon Valley Bank | ||||
 | Pharmazz | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.22M | Series A | 6/11/2025 | $25M | $216.61M | $5.89 | Sun Pharma | ||||
 | Pyxis Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $194.5M | Series B | 3/30/2021 | $172.5M | $273.43M | $10.47 | Arix Bioscience, RTW Investments, Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, Tekla Capital Management, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital, Laurion Capital Management, Logos Capital, LifeSci Venture Partners, Leaps by Bayer, Agent Capital, Ipsen Ventures, Longwood Fund, 3E Bioventures | ||||
 | Rapport Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.18M | Series B | 8/7/2023 | $150M | $409.19M | $1.68 | Cormorant Asset Management, Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital, Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation | ||||
 | Scipher Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.76M | Series D | 2/24/2022 | $120.72M | $498.65M | $38.12 | Cowen Healthcare Investments, Neuberger Berman, Hitachi Ventures, Laurion Capital, Monashee Investment Management, Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, Alumni Ventures | ||||
 | Septerna | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225M | Series B | 7/11/2023 | $150M | $313.42M | $1.23 | RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital | ||||
 | Svelte Medical Systems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $153.65M | Series C | 4/23/2021 | $11.89M | $396.2M | $321.83 | Undisclosed Investors | ||||
 | Syapse | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $201.76M | Series G-1 | 2/2/2021 | $41.21M | $192.94M | $0.50 | Ally Bridge Group, Northpond Ventures | ||||
 | Elektrofi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $284.44M | Series C | 8/8/2024 | $96.45M | $402.83M | $14.04 | Undisclosed Investors | ||||
 | Medly Pharmacy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $297.45M | Series C-1 | 7/29/2022 | $51.86M | $389.1M | $0.20 | Undisclosed Investors | ||||